Sommetrics Launches Pivotal Clinical Study of Its aerSleep II Product to Treat Sleep Apnea; Raises $11 Million in Series C Preferred Financing
VISTA, Calif. — September 29, 2021 — Sommetrics, a private company developing products and services to improve sleep health, today announced the launch of the pivotal clinical trial of its aerSleep® II device for the treatment of obstructive sleep apnea (OSA).
Sommetrics Receives IDE Approval From the FDA to Begin SUPRA Trial of aerSleep II for Treating Sleep Apnea
VISTA, Calif. — April 29, 2021 — Sommetrics is pleased to announce US Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application to conduct a pivotal in-home clinical trial of its aerSleep II system.
Sommetrics Receives FDA Breakthrough Device Designation for Its aerSleep II Product to Treat Sleep Apnea
Sommetrics, a private company developing products and services to improve sleep health, today announced its lead sleep apnea product, aerSleep II, has received FDA Breakthrough Device designation. This program allows for additional FDA feedback to sponsors during the pre-marketing phase…
Sommetrics Receives ISO 13485:2016 Certification
Sommetrics, Inc., which provides products to treat airway obstruction during sleep and in acute care settings, announced today that its quality management system has been certified to the rigorous ISO 13485:2016 standard. During the audit process required for certification, Sommetrics was also evaluated and found to be in compliance…
Sommetrics and aerFree, LLC Contributing to Treatment of COVID-19
Sommetrics, Inc. a company providing products and services to improve sleep quality, and its partially owned affiliate, aerFree, LLC, which is dedicated to improving acute airway management, today announced the donation of their aerFree® product to leading academic centers to assist in the management of COVID-19 respiratory impairment.
Sommetrics Completes Study of New Sleep Apnea Treatment in Ethnic Japanese Subjects
Sommetrics, a company dedicated to developing state of the art products to treat obstructive sleep apnea (OSA), today announced the completion of clinical study SOM-014. This trial evaluated the safety, tolerability and effectiveness of the Sommetrics aerSleep™ product in ethnic Japanese subjects with obstructive sleep apnea (OSA).
Sommetrics Chosen as a 2019 Red Herring Top 100 North America Winner
PASADENA, Calif. — MAY 23, 2019 — Sommetrics today announced that they have been named as one of the winners of Red Herring’s 2019 Top 100 North America, recognizing the continent’s most exciting and innovative private technology companies. The winners, celebrated at a special awards ceremony at the Westin Pasadena hotel, have been chosen from thousands of entrants…
Sommetrics Selected to Present at the Respiratory Innovation Summit
SAN DIEGO, Calif. — MAY 14, 2019 — Sommetrics, a company providing products and services to improve sleep quality, today announced it has been selected to be one of five companies to present at the airways symposium of the Respiratory Innovation Summit in Dallas on May 17, 2019. This Summit is a yearly event held in advance of the American Thoracic Society’s…
Sommetrics Selected to Participate in Red Herring Top 100 Competition
SAN DIEGO, Calif. — MAY 7, 2019 — Sommetrics, a company dedicated to developing state-of-the-art products to treat obstructive sleep apnea (OSA), today announced it has been selected to participate in the annual Red Herring Top 100 competition in Los Angeles on May 15, 2019. Sommetrics was selected based on a rigorous vetting process which evaluates…
Industry Leader David Schlotterbeck Joins the Sommetrics Advisory Board
SAN DIEGO, Calif. — JUNE 12, 2018 — Sommetrics, a company providing products and services to improve sleep quality, today announced it has added industry leader David Schlotterbeck to its advisory board. The company recently received Health Canada approval for its sleep apnea therapy system, aerSleepTM, allowing it to be marketed in Canada.